EAY191N4
OPEN TO ACCRUAL
Ph2 Randomized Selumetinib, Olaparib or Selumetinib in Patients w/Ovarian and Endometrial Cancer
GOG3069
OPEN TO ACCRUAL
Ph2 Study of Alpelisib & Fulvestrant for PIK3CA-mutated Estrogen Receptor Endometrial Cancers
GOG3083
OPEN TO ACCRUAL
Ph 3 Trial of Selinexor for Patients w/ p53 Wild Type, Advanced, or Recurrent Endometrial Carcinoma
GOG3104
OPEN TO ACCRUAL
Randomized Open Label Ph3 study of Sacituzumab Govitecan VS Phys Choice in Endometrial Cancer
NRGGY028
OPEN TO ACCRUAL
Ph1B and Randomized PhII trial of Megestrol Acetate w/ or w/o Ipatasertib in Endometrial Cancer